Clinical trials: Epithelial Neoplasms, Malignant
Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Acinar Cell Carcinoma
Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of vaccine therapy when given together with sargramostim in treating patients with locally advanced or metastatic pancreatic cancer that cannot be removed by surgery.
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT00669734
- Testing
- Falimarev, Inalimarev, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Esophageal Cancer
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
- Conditions
- Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer
- Trial name
- NCT05983432
- Testing
- BL-B01D1
- Where
- 37 sites in United States, France and 3 more
- Volunteers
- 540 people
- Sponsor
- SystImmune Inc.
Liver Neoplasms
Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma
The purpose of the study is to determine whether seocalcitol is effective in the treatment of advanced primary liver cancer (hepatocellular carcinoma [HCC]).
- Trial name
- NCT00051532
- Testing
- Seocalcitol
- Where
- 5 sites in Canada, France and 3 more
- Volunteers
- 700 people
- Sponsor
- LEO Pharma
Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion
NAXIVA is a study of axitinib in patients with metastatic and non-metastatic renal cell carcinoma with venous invasion. Patients will be given axitinib (twice daily) for 8 weeks (at an escalated dose) and the response of the…
- Conditions
- Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Non-metastatic Renal Cell Carcinoma
- Trial name
- NAXIVA (NCT03494816)
- Testing
- Axitinib Oral Tablet
- Where
- 7 sites in United Kingdom
- Volunteers
- 24 people
- Sponsor
- Scottish Clinical Trials Research Unit
Delayed Platelet Engraftment, Neuroblastoma
Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma
The goal of this clinical trial is to learn if hetrombopag promotes platelet engraftment in neuroblastoma children undergoing autologous hematopoietic stem cell transplantation.
- Conditions
- Delayed Platelet Engraftment, Neuroblastoma, Autologous Hematopoietic Stem Cell Transplantation
- Trial name
- NCT06818916
- Testing
- Hetrombopag
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Children's Hospital
Carcinoma Cervix,Stage III
Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix
The primary aim of the trial is to study the impact of nelfinavir on 3 year disease free survival in patients with advanced carcinoma of cervix receiving standard chemoradiation (Cisplatin and Radiotherapy).
- Trial name
- NELCER (NCT03256916)
- Testing
- Nelfinavir, Cisplatin, Pelvic EBRT and Brachytherapy
- Where
- India
- Volunteers
- 348 people
- Sponsor
- Tata Memorial Hospital
Cervical Carcinoma, Adenocarcinoma
PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer
This is an international, multicenter and randomized open-label phase III study designed to demonstrate, in patients with stage IIIC1 cervical cancer, whether para-aortic lymphadenectomy followed by tailored chemoradiation is…
- Conditions
- Cervical Carcinoma, Adenocarcinoma, Adenosquamous Carcinoma
- Trial name
- PAROLA (NCT05581121)
- Testing
- Standard treatment: Control arm, Experimental arm
- Where
- 37 sites in Czechia, France and 2 more
- Volunteers
- 510 people
- Sponsor
- Institut Claudius Regaud
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Non-Small Cell Lung Cancer, PET/CT
FAP-targeted PET/NIR in Lung Malignant Tumors
Single center, prospective, diagnostic study. Patients with stage II-IIIB resectable NSCLC diagnosed by pathology were included.
- Conditions
- Non-Small Cell Lung Cancer, PET/CT, Neoadjuvant Therapy
- Trial name
- NCT07498933
- Testing
- PET/CT scans
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University People's Hospital
Medulloblastoma, Central Nervous System Tumors
Clinical Studies of Gemcitabine-Oxaliplatin
These are Phase 2 single-arm studies of gemcitabine in combination with oxaliplatin in refractory or relapsing pediatric solid tumors.
- Conditions
- Medulloblastoma, Central Nervous System Tumors, Neuroblastoma, Osteosarcoma
- Trial name
- NCT00407433
- Testing
- Gemcitabine (Gemzar®), Oxaliplatin (Eloxatin®)
- Where
- France
- Volunteers
- 156 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Malignant Mesothelioma
Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma
RATIONALE: Patient abstract not available PURPOSE: Patient abstract not available
- Trial name
- NCT00004033
- Testing
- liposomal NDDP, therapeutic thoracoscopy
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Locally Advanced Hepatocellular Carcinoma
Natural Killer (NK) Cell Therapy in Locally Advanced HCC
This Phase 2a trial will evaluate the safety and efficacy of NK cell therapy combined with the hepatic artery infusion chemotherapy (HAIC) in patients with intermediate and/or locally advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT05040438
- Testing
- Vax-NK/HCC
- Where
- South Korea
- Volunteers
- 17 people
- Sponsor
- Vaxcell Bio, Co., Ltd.
HBV
Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.
This is a retrospective prospective, open-label, multicenter clinical study aiming to recruit 400 individuals with a family history of liver cancer to explore the clinical cure rate and the effectiveness, feasibility, and safety…
- Trial name
- NCT06746701
- Testing
- Peg-IFNα-2b combined with NA, Nucleotide Analogues
- Where
- 4 sites in China
- Volunteers
- 400 people
- Sponsor
- Xiangya Hospital of Central South University
Anaplastic Astrocytoma, Brain Stem Glioma
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
This phase I/II trial studies the side effects and the best dose of veliparib when given together with radiation therapy and temozolomide and to see how well they work in treating younger patients newly diagnosed with diffuse…
- Conditions
- Anaplastic Astrocytoma, Brain Stem Glioma, Childhood Mixed Glioma, Fibrillary Astrocytoma
- Trial name
- NCT01514201
- Testing
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- 12 sites in United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Urothelial Carcinoma
A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients
An autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients.
- Trial name
- NCT04383067
- Testing
- Tumor Infiltrating Lymphocytes (TIL), Proleukin
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Sheba Medical Center
Medullary Thyroid Cancer
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
This is a real world study aiming to observe the efficacy and safety of Anlotinib capsules in patients with advanced medullary thyroid carcinoma, and to summarize the treatment experience in a broad population of patients.
- Trial name
- NCT05830500
- Testing
- Anlotinib Hydrochloride Capsule
- Where
- 19 sites in China
- Volunteers
- 360 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Hepatocellular Carcinoma (HCC)
Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer
This trial is an open-label, dose-escalation, and randomized controlled Phase Ib/II clinical study for second-line treatment in participants with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT07282509
- Testing
- HA131, Enlonstobart Injection, Pembrolizumab Injection
- Volunteers
- 116 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Urothelial Carcinoma
A Prospective, Multi-centre, Single-blinded Study of UroCAD for Urothelial Carcinoma Diagnosis and Follow-up
Urothelial carcinoma (UC) is common malignancy and is considered to be one of the costliest cancers. The traditional diagnostic methods of UC present with some shortcomings.
- Trial name
- NCT04432909
- Testing
- The level of CNV
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Changhai Hospital
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04389632
- Testing
- sigvotatug vedotin, pembrolizumab, cisplatin
- Where
- 158 sites in United States, France and 5 more
- Volunteers
- 1,006 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Hepatocellular Carcinoma
Body Composition Analysis in Patients Undergoing Chemoembolization
Hepatocellular carcinoma represents 80-90% of primary hepatic malignant tumors. 80% of patients with hepatocellular carcinoma are associated with cirrhosis.
- Trial name
- NCT01777698
- Where
- Mexico
- Volunteers
- 21 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.